Short answer
Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K current report with the SEC on June 23, 2026 reporting Item 8.01 (Other Events). Phase 2 EoE trial fully enrolled with 95 adults across 41 U.S. sites.
Phathom Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 2 EoE trial fully enrolled with 95 adults across 41 U.S. sites
- VOQUEZNA 20 mg randomized against placebo for 12 weeks, followed by 12-week open-label extension
- Topline results anticipated in fourth quarter 2026, creating a near-term clinical catalyst
- Positive data could support FDA discussions on pediatric development and potential regulatory exclusivity extension
- Key risks include delayed analysis, mixed efficacy, safety issues, competition, and failure to secure EoE approval
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Phathom Pharmaceuticals, Inc. 8-K filings
Get the next PHAT 8-K as it lands
Follow PHAT for push alerts, or ask the research agent what this filing means.